MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today broke ground at its Sheboygan, Wisconsin site, for the company’s first lateral flow membrane production facility in the United States. Lateral flow membranes are a key component in rapid diagnostic test kits for a variety of applications, including Covid-19 testing. The new facility is supported by a USD 136.7 million contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services.
“Our purpose is to positively impact life and health with science, and today’s ground-breaking exemplifies this commitment by adding physical capacity and expanding our regional network to meet the growing needs of our customers and ensure supply chain security,” said Matthias Heinzel, Member of the Executive Board of Merck KGaA, Darmstadt, Germany, and CEO Life Science. “This new, state-of-the-art facility will support the surge in demand experienced by our global in-vitro diagnostic manufacturing customers.”
“From COVID-19 rapid testing to cancer therapies, the work MilliporeSigma does helps promote the health and safety of our families and communities while creating good jobs for hardworking Wisconsinites, and I am glad to be celebrating their success today,” said Gov. Evers. “In addition to creating 60 new jobs in Sheboygan, this new facility will provide a major step forward in expanding domestic diagnostic testing as the company’s first lateral flow membrane production facility in the U.S., ensuring our state and country are ready to tackle any public health crisis that comes our way now and into the future.”